Sanyou bio mouse immune antibody customization service combines the advantages of animal immunization, phage display, and eukaryotic expression. It takes only 14 days for library construction, antibody screening, and sequence analysis, which is nearly 5 months shorter than the screening of traditional hybridoma technology. , , and efficiently facilitate the discovery of antibodies in various application such as treatment, research, diagnosis, and detection.
Case 1: Discovery of ADC antibody molecules
The antibody Ab1 is a humanized murine antibody that developed by Sanyou Bio. The in vitro and in vivo efficacy of the Ab1 was demonstrated to be comparable to the benchmark in terms of its activity in ADC killing assay and tumor growth inhibition.
Fig.1: Binding affinity of candidate antibodies on tumor cells by FACS. The results showed that the affinity of the candidate antibodies were comparable to that of the benchmark.
Fig.2: ADC Killing assay of Ab1 ADC drug. The results showed that the killing effect of the Ab1 ADC drug was comparable to that of the benchmark ADC drug.
Fig.3:The in vivo efficacy validation of Ab1 ADC drug. The results showed that the candidate antibody ADC was comparable to that of the benchmark ADC drug.
Fig. 1 Binding affinity determination by FACS
Fig. 2 Cytotoxicity determination by FACS
Fig. 3 Tumor growth inhibition
Case 2: Development of immunomodulatory drugs
The antibody 47-92 is a humanized murine antibody that developed by Sanyou Bio. The candidate molecule 47-92 is shown to have 9-fold higher affinity than the benchmark lemzoparlimab, comparable blocking activity, and lower hematotoxicity.
Fig.4: The affinity of the candidate antibody 47-92 to human CD47 Fc tag protein was tested by biolayer Interferometry (BLI). The experimental results showed that the affinity of the 47-92 was 9 times higher than that of the benchmark lemzoparlimab.
Fig.5: In vitro agglutination assay. The results showed that the candidate antibody 47-92 had the weaker binding capacity to erythrocytes, which minimizes the blood coagulation effect of the 47-92. (F4AM4 is a candidate antibody from other library)
Fig.6: The activity of antibodies in blocking cell surface proteins by flow cytometry. The figure suggests that the candidate antibody showed good blocking activity.